Literature DB >> 26173587

CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Sandra Lazzaro1, Cinzia Giovani1, Simona Mangiavacchi1, Diletta Magini1, Domenico Maione1, Barbara Baudner1, Andrew J Geall2, Ennio De Gregorio1, Ugo D'Oro1, Cecilia Buonsanti1.   

Abstract

Self-amplifying mRNAs (SAM(®) ) are a novel class of nucleic acid vaccines, delivered by a non-viral delivery system. They are effective at eliciting potent and protective immune responses and are being developed as a platform technology with potential to be used for a broad range of targets. However, their mechanism of action has not been fully elucidated. To date, no evidence of in vivo transduction of professional antigen-presenting cells (APCs) by SAM vector has been reported, while the antigen expression has been shown to occur mostly in the muscle fibres. Here we show that bone-marrow-derived APCs rather than muscle cells are responsible for induction of MHC class-I restricted CD8 T cells in vivo, but direct transfection of APCs by SAM vectors is not required. Based on all our in vivo and in vitro data we propose that upon SAM vaccination the antigen is expressed within muscle cells and then transferred to APCs, suggesting cross-priming as the prevalent mechanism for priming the CD8 T-cell response by SAM vaccines.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  antigen-presenting cells; cross-presentation; muscle cells; nucleic-acid-based vaccines; self-amplifying mRNA

Mesh:

Substances:

Year:  2015        PMID: 26173587      PMCID: PMC4582972          DOI: 10.1111/imm.12505

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  56 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

2.  In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model.

Authors:  C W Mandl; J H Aberle; S W Aberle; H Holzmann; S L Allison; F X Heinz
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

Review 3.  The ReNAissanCe of mRNA-based cancer therapy.

Authors:  Sandra Van Lint; Dries Renmans; Katrijn Broos; Heleen Dewitte; Ine Lentacker; Carlo Heirman; Karine Breckpot; Kris Thielemans
Journal:  Expert Rev Vaccines       Date:  2014-09-29       Impact factor: 5.217

Review 4.  DNA vaccines: an historical perspective and view to the future.

Authors:  Margaret A Liu
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.

Authors:  James Heyes; Lorne Palmer; Kaz Bremner; Ian MacLachlan
Journal:  J Control Release       Date:  2005-10-03       Impact factor: 9.776

6.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

Authors:  Michael S D Kormann; Günther Hasenpusch; Manish K Aneja; Gabriela Nica; Andreas W Flemmer; Susanne Herber-Jonat; Marceline Huppmann; Lauren E Mays; Marta Illenyi; Andrea Schams; Matthias Griese; Iris Bittmann; Rupert Handgretinger; Dominik Hartl; Joseph Rosenecker; Carsten Rudolph
Journal:  Nat Biotechnol       Date:  2011-01-09       Impact factor: 54.908

7.  A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells.

Authors:  Kristin Hochweller; Jörg Striegler; Günter J Hämmerling; Natalio Garbi
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

8.  Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.

Authors:  Bo Jin; Richard Y Wang; Qi Qiu; Fuminaka Sugauchi; Teresa Grandinetti; Harvey J Alter; J Wai-Kuo Shih
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

Review 9.  RNA: the new revolution in nucleic acid vaccines.

Authors:  Andrew J Geall; Christian W Mandl; Jeffrey B Ulmer
Journal:  Semin Immunol       Date:  2013-06-02       Impact factor: 11.130

Review 10.  Therapeutic and prophylactic applications of alphavirus vectors.

Authors:  Gregory J Atkins; Marina N Fleeton; Brian J Sheahan
Journal:  Expert Rev Mol Med       Date:  2008-11-11       Impact factor: 5.600

View more
  27 in total

1.  Immune responses of dendritic cells combined with tumor-derived autophagosome vaccine on hepatocellular carcinoma.

Authors:  Yongxiang Yi; Jianbo Han; Liang Zhao; Chunying Wang; Yuan Fang; Qiang Wei; Liang Hu; Junmao Liu; Yufeng Zhang; Lili Wang
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

Review 2.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

Review 3.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

Review 4.  mRNA Vaccines: Why Is the Biology of Retroposition Ignored?

Authors:  Tomislav Domazet-Lošo
Journal:  Genes (Basel)       Date:  2022-04-20       Impact factor: 4.141

Review 5.  DNA Vaccines-How Far From Clinical Use?

Authors:  Dominika Hobernik; Matthias Bros
Journal:  Int J Mol Sci       Date:  2018-11-15       Impact factor: 5.923

6.  Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice.

Authors:  Katherine L Mallory; Justin A Taylor; Xiaoyan Zou; Ishita N Waghela; Cosette G Schneider; Michael Q Sibilo; Neeraja M Punde; Leah C Perazzo; Tatyana Savransky; Martha Sedegah; Sheetij Dutta; Chris J Janse; Norbert Pardi; Paulo J C Lin; Ying K Tam; Drew Weissman; Evelina Angov
Journal:  NPJ Vaccines       Date:  2021-06-18       Impact factor: 7.344

7.  Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.

Authors:  Diletta Magini; Cinzia Giovani; Simona Mangiavacchi; Silvia Maccari; Raffaella Cecchi; Jeffrey B Ulmer; Ennio De Gregorio; Andrew J Geall; Michela Brazzoli; Sylvie Bertholet
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

Review 8.  New Vaccine Technologies to Combat Outbreak Situations.

Authors:  Susanne Rauch; Edith Jasny; Kim E Schmidt; Benjamin Petsch
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

Review 9.  A new generation of vaccines based on alphavirus self-amplifying RNA.

Authors:  María Cristina Ballesteros-Briones; Noelia Silva-Pilipich; Guillermo Herrador-Cañete; Lucia Vanrell; Cristian Smerdou
Journal:  Curr Opin Virol       Date:  2020-09-05       Impact factor: 7.090

Review 10.  Self-amplifying RNA vaccines for infectious diseases.

Authors:  Kristie Bloom; Fiona van den Berg; Patrick Arbuthnot
Journal:  Gene Ther       Date:  2020-10-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.